Integra LifeSciences Holdings Corporation (IART)

NASDAQ: IART · IEX Real-Time Price · USD
59.61
-0.88 (-1.45%)
Feb 3, 2023, 4:00 PM EST - Market closed
-1.45%
Market Cap 4.98B
Revenue (ttm) 1.57B
Net Income (ttm) 172.99M
Shares Out 83.52M
EPS (ttm) 2.06
PE Ratio 28.94
Forward PE 16.18
Dividend n/a
Ex-Dividend Date n/a
Volume 373,124
Open 59.92
Previous Close 60.49
Day's Range 58.91 - 60.65
52-Week Range 40.67 - 68.29
Beta 1.13
Analysts Buy
Price Target 59.57 (-0.07%)
Earnings Date Feb 22, 2023

About IART

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumenta... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Aug 16, 1995
Employees 3,800
Stock Exchange NASDAQ
Ticker Symbol IART
Full Company Profile

Financial Performance

In 2021, IART's revenue was $1.54 billion, an increase of 12.43% compared to the previous year's $1.37 billion. Earnings were $169.08 million, an increase of 26.28%.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for IART stock is "Buy." The 12-month stock price forecast is $59.57, which is a decrease of -0.07% from the latest price.

Price Target
$59.57
(-0.07% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Integra (IART) Could Beat Earnings Estimates Again

Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 week ago - Zacks Investment Research

Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president a...

1 month ago - GlobeNewsWire

Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope

With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.

1 month ago - Zacks Investment Research

Integra LifeSciences Completes the Acquisition of Surgical Innovation Associates

PRINCETON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed i...

2 months ago - GlobeNewsWire

Integra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase

Acquisition will add distinct new product solution for plastic and reconstructive surgery to address clinical needs and improve patient outcomes

2 months ago - GlobeNewsWire

Integra's (IART) Q3 Earnings Top, Gross Margin Declines

Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.

3 months ago - Zacks Investment Research

Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates

Integra (IART) delivered earnings and revenue surprises of 19.44% and 1.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Integra LifeSciences Reports Third Quarter 2022 Financial Results

PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third...

3 months ago - GlobeNewsWire

Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Integra LifeSciences to Host Third Quarter 2022 Financial Results Conference Call on October 26, 2022

PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release third quarter 2022 financial res...

4 months ago - GlobeNewsWire

Integra LifeSciences Announces Key Executive Appointment

PRINCETON, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today announced the appointment of Harvinder Singh as executive vice president and president...

4 months ago - GlobeNewsWire

Integra LifeSciences Publishes Its Inaugural ESG Report

The report underscores the company's long-standing commitment to improving the health of patients and the planet. The report underscores the company's long-standing commitment to improving the health ...

4 months ago - GlobeNewsWire

Here's Why Investors Should Retain Integra (IART) Stock for Now

Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.

5 months ago - Zacks Investment Research

Integra LifeSciences Announces Participation in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in t...

5 months ago - GlobeNewsWire

Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO

PRINCETON, N.J., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Dr. Richard Caruso, founde...

6 months ago - GlobeNewsWire

Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut

Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.

6 months ago - Zacks Investment Research

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

Integra (IART) delivered earnings and revenue surprises of 2.50% and 0.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Integra LifeSciences Reports Second Quarter 2022 Financial Results

PRINCETON, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the secon...

6 months ago - GlobeNewsWire

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Integra LifeSciences Appoints Renee Lo as Director

PRINCETON, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Renee Lo to...

7 months ago - GlobeNewsWire

Integra LifeSciences to Host Second Quarter 2022 Financial Results Conference Call on July 27, 2022

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) --) Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2022 financial ...

7 months ago - GlobeNewsWire

Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

8 months ago - Zacks Investment Research

Integra (IART) Gains From Innovation Amid Cost Constraints

Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.

8 months ago - Zacks Investment Research

Integra (IART) Q1 Earnings Top Estimates, Margins Expand

Integra's (IART) updated 2022 financial guidance calls for strong year-over-year organic growth.

9 months ago - Zacks Investment Research